Aficamten
AssetAlso CK-3773274
Inhibits cardiac myosin to reduce excessive contractility in hypertrophic cardiomyopathy.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- MYH7
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Symptomatic hypertrophic cardiomyopathy
Phase 2, Enrolling by invitation, NCT04848506, clinicaltrials.gov, 16 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors4
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.